Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.54 - $3.46
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.58M
Market Cap
$796.39M
Enterprise Value$260.10M
Total Cash (Recent Filing)$607.72M
Total Debt (Recent Filing)$203.37M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 05, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding342,272,740
10 Day Avg. Volume3,728,902
30 Day Avg. Volume4,577,627
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue18.12
Enterprise Value/Gross Profit65.78
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$7.80Price Target Upside198.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIBTROZI generated $1.2M in product sales within 13 business days after receiving FDA approval.
Regulatory ApprovalNuvation Bio received full FDA approval for its drug Ibtrozi in line agnostic ROS1+ NSCLC.
Strategic PositioningNuvation Bio has a 9-18+ month head start over its competitor Nuvalent in the ROS1+ lung cancer space.
Bears Say
Clinical RisksRisks include negative clinical proof-of-concept data for any of the company's drug-drug conjugate (DDC) candidates or any of the other pipeline programs.
Market RisksRisks include poorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Short InterestShort interest is 15.5% of the float.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $3.46 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $796.39M.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Nov 05, 2025 which is in 82 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Aug 07, 2025. The company reported -$0.17 earnings per share for the quarter, the consensus estimate of -$0.17 by $0.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.17.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 342,272,740 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.17 in its last earnings report, expectations of -$0.17. Following the earnings report the stock price went down -0.426%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.80 (198.85% Upside)
$7.80 (198.85% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $986.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.09%
12-Months-Change
Fundamentals
Return on Equity
-64.40%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing a proprietary pipeline of novel oncology drug candidates. Nuvation Bio aims to address unmet medical needs by targeting multiple tumor types with its differentiated therapeutic approaches.
NUVB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong confidence in the potential approval and market launch of taletrectinib. The company highlighted its robust financial position and pipeline development, although there were concerns about increased expenses and gaps in patient testing and diagnosis.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$7.80
▲(198.85% Upside)
Technical Analysis
Arbutus Biopharma
―
Xencor
―
Rocket Pharmaceuticals
―
Praxis Precision Medicines
―
Bicara Therapeutics Inc.
―
Ownership Overview
27.23% Insiders
15.52% Mutual Funds
0.05% Other Institutional Investors
47.48% Public Companies and Individual Investors